Ashland launches permexa™ sodium caprate to advance oral biologics delivery
核心洞察
Ashland Inc. (搜索) has launched permexa™ sodium caprate (搜索), a high-performance intestinal permeation enhancer for oral peptide, biologic, and low-permeability drug products.
The excipient targets rapidly expanding GLP-1 agonist pipelines and related therapeutic areas, addressing formulation consistency, process robustness, and scalability barriers.
The product combines established sodium caprate functionality with an IP-protected process to improve powder flow, compressibility, and formulation consistency for tablet manufacturing.
Ashland Inc. (搜索) (NYSE: ASH) has announced the launch of permexa™ sodium caprate (搜索), a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic, and low-permeability drug products, including rapidly expanding GLP-1 agonists (搜索) and related therapeutic pipelines. The announcement, made on August 24, 2026, in Wilmington, Delaware, comes amid significant market momentum in oral peptide and biologics development.
Pharmaceutical companies continue to invest heavily in oral alternatives to injectable therapies, driven by the potential to improve patient convenience, enhance treatment adherence, and unlock new therapeutic opportunities. As a result, pipelines across GLP-1s, diabetes (搜索) and weight loss, metabolic disorders (搜索), endocrine therapeutics, and other peptide-based medicines continue to expand.
Addressing formulation and manufacturing barriers
Despite growing investment and encouraging clinical progress, developers continue to face important challenges as programs move from concept through development and manufacturing. Permeability enhancement remains critical for oral drug products, but formulation consistency, process robustness, and scalability are increasingly recognized as key barriers to successful commercialization.
Ashland permexa™ sodium caprate (搜索) was engineered to help address these challenges by combining established sodium caprate functionality with improved pharmaceutical processing performance. The excipient is designed with an IP-protected process to support more robust tablet manufacturing through improved powder flow, enhanced compressibility, and greater formulation consistency, while maintaining the permeability enhancement characteristics required for oral drug delivery applications. The result is a solution intended not only for laboratory success, but also for real-world pharmaceutical development and manufacturing environments where reproducibility, scalability, and process robustness are essential.
Strong pre-launch engagement
The Ashland launch follows strong interest from pharmaceutical developers worldwide. Ahead of the commercial launch, the company recorded engagement with multiple pharmaceutical, biotech, and CDMO organizations globally, spanning sampling activities, technical evaluations, pre-launch sales, benchmarking studies, and formulation development discussions. Customer feedback has been overwhelmingly positive on the product's differentiated properties.
"The rapid growth of oral peptide development is creating demand for excipients that support both biological performance and pharmaceutical manufacturability," said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. "Permexa™ sodium caprate (搜索) was engineered to help customers address complex challenges and move more confidently from formulation through commercialization. The level of engagement we have seen prior to launch demonstrates the importance of solutions that support both drug delivery performance and scalable manufacturing."
A multi-stage oral biologics strategy
Caroline Cooreman, strategy director, Life Sciences, Ashland, indicated the company's ambitions extend beyond this single product. "Consequently, Ashland is not stopping here. We have developed a multi-stage strategy to support the pharmaceutical market with essential excipients for the oral delivery of biologics. We have multiple additional products in the pipeline and recognize important synergies with our vinyl pyrrolidone and derivatives (VP&D) portfolio. We are already actively servicing this market with our established VP&D portfolio, which will be further strengthened by our oral biologics' portfolio expansion," she concluded.
Ashland Inc. (搜索) is a global additives and specialty ingredients company serving customers in markets including pharmaceutical, with approximately 2,900 employees operating in more than 100 countries.